Delving into the Latest Updates on Pembrolizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Lambrolizumab, Pembrolizumab (Genetical Recombination), Pembrolizumab (genetical recombination) (JAN)

+ [11]

Target

PD-1

Action

inhibitors

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [13]

Active Indication

Platinum-Resistant Primary Peritoneal CarcinomaPlatinum-Resistant Epithelial Ovarian CarcinomaMismatch repair-deficient Colonic Cancer+ [325]

Inactive Indication

Acral Lentiginous Malignant MelanomaAcute Myeloid LeukemiaAcute myeloid leukemia with mutated NPM1+ [114]

Originator Organization

Merck & Co., Inc.

Active Organization

MSD R&D (China) Co. Ltd.

Merck Sharp & Dohme Corp.Merck Sharp & Dohme LLC

+ [16]

Inactive Organization

Merck Sharp & Dohme (Ireland) Ltd.

Turnstone Biologics Corp.

Viralytics Pty Ltd.

License Organization

Nektar Therapeutics

NeoImmuneTech, Inc.

Canada Pension Plan Investment Board

+ [80]

Drug Highest PhaseApproved

First Approval Date

United States (04 Sep 2014),

Melanoma

RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), PRIME (European Union), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), Breakthrough Therapy (China), Priority Review (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 93660H

Source: *****

Sequence Code 93670L

Source: *****

This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with advanced squamous non-small cell lung cancer (NSCLC) or squamous cell carcinoma of head and neck (SCCHN).

Start Date20 May 2027

Sponsor / Collaborator

Lineberger Comprehensive Cancer Center

NCT07037004

/ RecruitingPhase 2IIT

Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)

This phase II trial compares the effect of adding a Live Biotherapeutic Product called CBM588 to pembrolizumab versus pembrolizumab alone in preventing return of disease (recurrence) after surgery for patients with renal cell cancer. Pembrolizumab is an immune checkpoint inhibitor. Immunotherapy with monoclonal antibodies such as pembrolizumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pembrolizumab is approved for the treatment of renal cell cancer after surgery. Research has shown that changes to the composition of the healthy bacteria in the body (the microbiome), may improve a patient's response to treatment with immunotherapy. CBM588, a Live Biotherapeutic Product (LBP) containing a bacteria called Clostridium butyricum, has been shown to improve outcomes in patients treated with immunotherapy for other types of cancer. Adding CBM588 to treatment with pembrolizumab after surgery may cause changes in the microbiome that improve patient response to treatment and reduce disease recurrence, compared to pembrolizumab alone.

Start Date01 Jan 2027

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT07603856

/ RecruitingPhase 2IIT

A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy

Current clinical trials testing the combination of immunotherapy with radiotherapy.

Start Date12 Dec 2026

Sponsor / Collaborator

The University of Chicago

100 Clinical Results associated with Pembrolizumab

Login to view more data

100 Translational Medicine associated with Pembrolizumab

Login to view more data

100 Patents (Medical) associated with Pembrolizumab

Login to view more data

11,124

Literatures (Medical) associated with Pembrolizumab

31 Dec 2026·Human Vaccines & Immunotherapeutics

Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report

Article

Author: Zhuang, Yihan ; Chen, Qiongshan ; Lin, Wen ; Chen, Zipei

Anaplastic thyroid cancer is a notoriously aggressive malignancy with a dismal prognosis, typically associated with a median overall survival of less than one year. Therapeutic alternatives are particularly limited for patients without actionable driver mutations. Here, we report a case of BRAF V600E wild-type, PD-L1-positive (tumor proportion score of 80%) anaplastic thyroid cancer with residual/relapsed disease following surgery and subsequent progression on multi-targeted tyrosine kinase inhibitor therapy. The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.

31 Dec 2026·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study

Article

Author: Wang, Ting ; Chen, Jinyun ; Ouyang, Bing ; Chen, Li ; Chen, Wenzhi

BACKGROUND:

This single-arm, open-label clinical trial aimed to evaluate the preliminary safety, efficacy and feasibility of focused ultrasound ablation surgery (FUAS) sequential with immune checkpoint inhibitors (ICIs) in patients with driver-gene wild-type non-small cell lung cancer (NSCLC) and liver metastases.

MATERIALS AND METHODS:

Ten eligible patients received two cycles of FUAS sequential with ICIs. The ICIs used include Camrelizumab (7/10), Pembrolizumab (3/10) and Serplulimab used for immune rechallenge (1/10). Follow-up was conducted every 6 weeks ± 3 days, including imaging and hematological assessments. Treatment-related adverse events (AEs) were documented anytime.

RESULTS:

All participants demonstrated stable tolerability and safety in this trial. Immediate post-FUAS ablation rates ranged from 73% to 80%. The median follow-up time is 84 days (IQR, 42-127 days). From baseline to week 18, continuous shrinkage of both hepatic metastatic and target lesions was observed. The DCR of the tumor has reached 80% since the 2nd follow-up (12 weeks), and it remains at 50% until the 4th follow-up (24 weeks).

CONCLUSION:

FUAS sequential with ICIs suggests preliminary safety, activity and feasibility in treating driver-gene wild-type NSCLC patients with liver metastases, further validation is needed.

31 Dec 2026·OncoImmunology

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma

Article

Author: Cocolakis, Eftihia ; Cailhier, Jean-François ; Lapointe, Réjean ; Thébault, Paméla ; Shechtman, Yelena ; Lepage, Stéphanie ; Letendre, Caroline ; Le, Huy ; Dionne, Jeanne ; Bélanger, Karl ; Jamal, Rahima ; Lambert, Caroline ; Miller Jr, Wilson H.

Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treated with pembrolizumab and CP. Peripheral blood was collected at baseline and after 2 cycles to characterize systemic immune activity by multiplex assays and flow cytometry. Seventy percent of patients received all 4 cycles of CP; 87% received pembrolizumab for 2 y or until progression. Grade 3 and higher adverse events (AEs) occurred in 50% of the patients. The overall response rate (ORR) and disease control rate (DCR) by irRC criteria were 43% and 53%, respectively. Median overall survival (OS) was 23.8 months. Objective response was associated with a lower frequency of naive CD8 T cells and low plasma CCL3 at baseline, along with a larger proportion of mature NK cells and of CD4 T cells expressing BTLA or LAIR-1. Survival rate was higher for patients with lower baseline of IL-6, IL-8, and CD4⁺CD39⁺ T cells. Following treatment, pro-inflammatory soluble factors increased in both responders and non-responders. Addition of CP to pembrolizumab in this study did not appear to result in a response or survival advantage and was less tolerable than immunotherapy alone. Correlative data point to peripheral signals to investigate further as potential biomarkers. Trial registration: clinicaltrials.gov, NCT02617849, registered on December 1st, 2015.

6,834

News (Medical) associated with Pembrolizumab

19 Jun 2026

·www.prnewswire.com

New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway

Drugmakers run the largest direct-to-consumer advertising category in the United States. New 5W research finds AI citation share does not follow the ad budget — it follows the drugs patients self-research. Eli Lilly and Novo Nordisk lead the answer. Merck makes the world's best-selling drug and ranks fifth. BOCA RATON, Fla., June 19, 2026 /PRNewswire/ -- 5W AI Communications, the AI Communications Firm and one of the largest independent public relations and digital marketing agencies in the United States, today released the Pharma / Rx AI Visibility Index 2026, with a focused cut on the gap between pharmaceutical direct-to-consumer ad spend and AI citation share. The Index is part of the 5W AI Visibility Index series, which tracks how leading brands are cited across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews. The Index ranks the top 25 pharmaceutical companies by AI citation share across more than 60 patient and consumer prompts run in Q2 2026 — five times per engine, in clean sessions. The Pharma DTC cut isolates one structural finding: the U.S. pharmaceutical industry spent an estimated $8 billion on direct-to-consumer advertising in 2024 — the largest category-level DTC ad commitment in the country — yet ad spend does not predict where the AI engines land. The headline numbers 12.5% — Estimated AI citation share held by Eli Lilly, the most-cited drugmaker. 11.5% — Novo Nordisk, citation co-leader on the back of Ozempic and Wegovy. ~$70 billion — Combined 2025 sales of Ozempic, Wegovy, Mounjaro, and Zepbound (GLP-1 receptor agonists). $5.6 trillion — Estimated size of the global pharmaceutical market. $1 trillion — Market cap milestone Eli Lilly briefly crossed — the first healthcare company to do so. 5th — Where Merck lands in citation rank, despite producing Keytruda, the best-selling prescription drug in the world. The top fifteen drugmakers by AI citation share — Q2 2026 01. Eli Lilly — Metabolic & GLP-1 — 12.5% 02. Novo Nordisk — Metabolic & GLP-1 — 11.5% 03. Pfizer — Diversified / vaccines — 8.5% 04. Johnson & Johnson — Diversified — 7.0% 05. Merck — Oncology — 6.0% 06. AbbVie — Immunology & inflammation — 5.0% 07. AstraZeneca — Oncology & specialty — 4.0% 08. Moderna — Vaccines & mRNA — 3.5% 09. Amgen — Biologics & specialty — 3.0% 10. Novartis — Specialty & gene therapy — 2.6% 11. Bristol Myers Squibb — Oncology & cardiovascular — 2.3% 12. GSK — Vaccines & respiratory — 2.0% 13. Sanofi — Immunology & vaccines — 1.8% 14. Gilead Sciences — Antivirals & oncology — 1.5% 15. Roche — Oncology & diagnostics — 1.3% Source: 5W analysis of AI-generated responses across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews, Q2 2026. Share represents the estimated proportion of company citations across 60+ tracked patient and consumer prompts. Remaining citation volume splits across ranks 16–25 and unranked companies. See full Top 25 and methodology at the source report. The structural finding: DTC spend does not buy citation share Pharma is the largest DTC advertising category in the U.S. — drugmakers spent an estimated $8 billion on consumer ads in 2024, with AbbVie, Pfizer, and Bristol Myers Squibb among the highest individual spenders. The Index finds that scale of spend does not translate into proportional AI citation share. AbbVie's Humira franchise — historically the most-advertised brand in U.S. healthcare — ranks sixth at an estimated 5.0%. Lilly and Novo combined hold roughly a quarter of all pharma citations in the test set, driven not by ad spend but by the public consumer-research footprint that Ozempic, Wegovy, Mounjaro, and Zepbound generated across earned media, PubMed, Wikipedia, and the business and health press. The mechanism is the structural difference between paid attention and AI-retrievable record. A 30-second TV spot can move share-of-voice for a quarter. A peer-reviewed trial readout in The New England Journal of Medicine, followed by sustained Reuters, STAT, and Fierce Pharma coverage, moves the answer surface for years. The engines retrieve the durable record, not the campaign. Quote from Ronn Torossian, Founder and Chairman, 5W AI Communications "Pharma is the largest direct-to-consumer ad category in America. The AI engines are not impressed. They name the companies whose drugs patients actually research — Eli Lilly and Novo Nordisk — not the companies running the most prime-time spots. AbbVie spent the most. Merck makes the best-selling drug on earth. Neither is the answer the chatbox returns. That is the gap. The pharmaceutical industry is paying for share-of-voice on a channel — television — that no longer routes to the buyer the same way. The buyer is in the chatbox, asking ChatGPT to compare Ozempic and Mounjaro. The companies that built the AI-retrievable record around those names own that answer. The ones still buying spots and hoping it carries through to the engines are funding the wrong channel." "AI Communications is a mix of journalism, psychology, and engineering." Six structural truths the Index documents Revenue rank does not predict citation rank. The highest-earning drugmakers are not the most-cited. A blockbuster drug pulls the company name with it. Ozempic and Mounjaro made Novo and Lilly household names. Self-researched conditions drive citations. Weight, diabetes, and immunology generate citations. Specialist-prescribed oncology does not. DTC advertising compounds into citations only when it feeds the editorial record. The spot itself is not retrievable; the coverage it generates is. Diffuse corporate structure dilutes citation share. Conglomerates and private companies under index. Patients now research before the appointment. Corporate citation share is upstream of the prescription conversation. Methodology 5W analyzed more than 60 common patient and consumer prompts across six sub-categories of the pharmaceutical market: metabolic and GLP-1, oncology, immunology and inflammation, vaccines and antivirals, cardiovascular and specialty, and generics and biosimilars. Each prompt was run five times per engine in clean sessions across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews. Citation sources tracked include the business and health editorial press (Reuters, Bloomberg, Fierce Pharma, STAT), reference sources (company filings, Wikipedia, Drugs.com), and brand-owned corporate content. Full methodology at 5wpr.com/ai-visibility-index/methodology. Important framing This Index measures AI citation share for corporate communications and marketing strategy purposes only. It is not medical advice. It does not rank drugs or companies on safety, efficacy, side effects, or value. It does not recommend any treatment. Medication decisions must be made with a qualified physician or pharmacist. Nothing in this report should be used to choose, start, stop, or change a prescription. About 5W 5W is the AI Communications Firm, building brand authority across the platforms where decisions now happen — ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews — alongside earned media, digital, and influencer channels. 5W combines public relations, digital marketing, Generative Engine Optimization (GEO), and proprietary AI visibility research to help clients measure and grow their presence in AI-driven buyer research. Founded in 2003, 5W is recognized as a Top U.S. PR Agency by O'Dwyer's, named Agency of the Year in the American Business Awards®, honored as a 2026 Top Place to Work in Communications by Ragan, and named to Digiday's WorkLife Employer of the Year list. 5W serves clients across B2C sectors — Beauty & Fashion, Consumer Brands, Entertainment, Food & Beverage, Health & Wellness, Travel & Hospitality, Technology, and Nonprofit — and B2B specialties including Corporate Communications, Reputation Management, Public Affairs, Crisis Communications, and Digital Marketing across Social, Influencer, Paid Media, GEO, and SEO. Learn more at 5wpr.com. Media contact 5W AI Communications — Press inquiries: [email protected] SOURCE 5W Public Relations 21% more press release views with Request a Demo

19 Jun 2026

·allsci.com

Mabwell’s Nectin-4 ADC challenges Pfizer’s Tivdak with 77% response rate in combination study

China-based Mabwell (688062.SH, 02493.HK) reported early-stage clinical data for its Nectin-4-targeting antibody-drug conjugate 9MW2821 (bulumtatug fuvedotin, BFv) in cervical cancer at the ESMO Gynaecological Cancers Congress in Copenhagen, with results that position the molecule as a potential competitor to Pfizer’s Tivdak (tisotumab vedotin) in the post-platinum setting — and, more ambitiously, as a first-line combination option if later-stage data hold. The monotherapy arm of NCT05216965, a Phase I/II study in recurrent or metastatic cervical cancer, enrolled 55 patients who had progressed on platinum-based chemotherapy with or without bevacizumab. Among 53 efficacy-evaluable patients, the confirmed objective response rate (cORR) was 32% and the disease control rate reached 81%. The headline survival figure — a median overall survival of 19.4 months, with a 24-month OS rate of 49% — is notable for a heavily pretreated population, though the single-arm design and modest sample size preclude direct comparison with approved agents. Cross-trial comparisons are limited, but tisotumab vedotin’s Phase III innovaTV 301 trial, which supported full FDA approval in April 2024, reported a median OS of approximately 11.5 months versus 9.5 months for chemotherapy in a similar post-platinum population. Combination data draw more attention A second potentially commercially significant dataset came from a Phase Ib/II study pairing BFv with Junshi Biosciences’ Loqtorzi (toripalimab), a PD-1 inhibitor approved by the US FDA for nasopharyngeal carcinoma but not for cervical cancer. Among 13 efficacy-evaluable patients — a very small cohort — the ORR was 77% and the disease control rate reached 100%. In the 10 treatment-naïve patients evaluable for response, the ORR was 80%. Adverse events were predominantly Grade 1–2, with no new safety signals identified. These numbers, while preliminary, are relevant because the first-line cervical cancer setting is currently anchored by Merck’s Keytruda (pembrolizumab) combined with platinum-based chemotherapy with or without Roche’s Avastin (bevacizumab), an approach restricted to patients with PD-L1 CPS ≥1. A chemotherapy-free ADC plus PD-1 combination that could demonstrate durable responses regardless of biomarker status would address a genuine gap — though the 13-patient efficacy dataset reported here is far too small to draw conclusions about clinical positioning. Strategic context Mabwell describes 9MW2821 as the first Nectin-4-directed ADC to enter Phase III trials for both cervical cancer and triple-negative breast cancer. Four pivotal Phase III studies are currently under way, with interim analyses for urothelial carcinoma monotherapy, urothelial carcinoma combination therapy, and cervical cancer monotherapy all planned for 2026. The company has secured FDA Fast Track Designation for three indications and Breakthrough Therapy Designation from China’s National Medical Products Administration for two indications. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

18 Jun 2026

·www.scripps.edu

Lab studies explain how new cancer drug works as it enters patient testing

Immunologists at Scripps Research show how a new, experimental drug revives immune cells to fight cancer. June 18, 2026 LA JOLLA, CA—For some people, cancer immunotherapies are life-changing. These treatments can turn the body’s own immune system against a tumor, either eliminating it or shrinking it enough to make surgery possible. But these therapies don’t work for everyone, can gradually stop working or can come with a host of side effects, including severe inflammation. A new experimental therapy aims to change that. Scripps Research scientists are testing SAR’877, a bispecific molecule designed to restore immune cells’ ability to fight cancer. The results of preclinical work are encouraging, and an ongoing phase 1/2 clinical trial is showing early signs of effectiveness even in those who have stopped responding to other immunotherapies. Now, new research published on April 30, 2026, in JCI Insight helps explain why: The drug revives exhausted T cells more precisely than existing approaches without triggering the dangerous inflammation that has limited similar drugs in the past. “What we showed is that you can deliver the immune-stimulating signal to the cells that need it most,” says John Teijaro, a professor at Scripps Research and co-senior author of the study. “This rescues their function more effectively than anything else we’ve seen in this setting.” The new molecule was designed to fight “T cell exhaustion”: a drop in activity that happens when immune cells face a chronic threat, such as a tumor or long-term infection. While that exhaustion evolved partly to protect the body’s tissues from an overactive immune response, in cases of cancer, it allows tumors to grow unchecked. Therapies that have been developed over the past few decades aim to stop this exhaustion. Checkpoint inhibitors like pembrolizumab work by removing a molecular brake called PD-1 that turns off the immune system’s T cells. On the other hand, cytokines like interleukin-15 (IL-15) can rev up immune cell activity—but this can lead to severe inflammation. As a bispecific molecule, SAR’877 takes a combined approach. It uses an antibody that targets PD-1 so that it binds directly to T cells and releases their brake. But attached to the antibody is also a purposefully weakened version of the cytokine IL-15. The weakened IL-15 has an effect only on nearby cells. And because it’s tethered to the PD-1 antibody, this cytokine primarily acts on exhausted T cells. To test whether the approach worked, Teijaro’s team turned to a model of chronic viral infection originally developed decades earlier in the lab of Scripps Research professor Michael Oldstone. This model has become one of immunology’s most trusted tools for testing whether a drug can revive immune function. Using a version of SAR’877 adapted for mice, Teijaro’s lab showed that the drug cleared the virus from the blood and kidneys more effectively than a PD-1-blocking antibody alone, untargeted IL-15 alone or both drugs given at once. Detailed analysis of immune cells revealed that SAR’877 selectively activated only certain groups of T cells already primed to respond to the virus rather than broadly stimulating all immune cells. One of the most unexpected findings from these experiments involved CD4+ “helper” T cells, which support other immune cells rather than directly attacking cancer cells. While cancer immunotherapy has largely focused on revving up CD8+ "killer" T cells, CD4+ cells appeared to play an unanticipated central role in the effectiveness of SAR’877. “We were surprised by the magnitude of the CD4+ response since we didn’t expect IL-15 to do much for those cells,” says Teijaro. “But we saw a dramatic increase in CD4+ activity, and when we removed those cells from mice, the drug’s benefit largely disappeared.” That observation suggests that more research is needed on how these overlooked cells could help turn up immune activity against viruses and cancers. The researchers then tested the drug’s effect on 12 different mouse tumor models. The drug shrank tumors in all 12 models and completely eliminated tumors in some mice, including more than two-thirds of those with liver cancer and breast cancer. Teijaro’s lab is now investigating whether combining SAR'877 with anti-inflammatory drugs could further reduce side effects and allow for higher, more effective doses, potentially allowing more patients to benefit. About SAR445877 (abbreviated as SAR’877/formerly KD050): SAR’877 is an investigational anti-PD-1/IL-15 fusion protein developed by the biopharmaceutical company Sanofi. Preclinical trials have been conducted by Sanofi and Scripps Research. Sanofi is currently evaluating SAR’877 in an ongoing phase 1/2 clinical trial in adults with advanced inoperable solid or metastatic tumors. Donald Shaffer, head of the Immunomodulation and Cell Reprogramming Cluster at Sanofi, is co-senior author of the study. In addition to Teijaro and Shaffer, authors of the study, “PD-1-targeted IL-15 mutein activates CD8+ and CD4+ T cells in infection and cancer,” include Isaraphorn Pratumchai, Jaroslav Zak, Maheeka Bimal and Kristi L. Marquardt of Scripps Research; and Marie Bernardo, Julien Tessier, Joon Sang Lee, AHyun Choi, Anthony M. Byers, Mikielia Devonish, Roberto Carrio, Dan Lu, Stella Martomo, Jeegar Patel, Yu-an Zhang, Ingeborg M. Langohr, Virna Cortez-Retamozo, Dinesh S. Bangari, Angela Hadjipanayis, Xiangming Li and Valeria R. Fantin of Sanofi. This work was supported by funding from Sanofi, Kadmon Corporation, the National Institutes of Health (5R01AI164744, K22CA292568), start-up funds from The University of Utah, and the Huntsman Cancer Foundation. For more information, contact press@scripps.edu See More News

ImmunotherapyClinical Study

100 Deals associated with Pembrolizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10574	Pembrolizumab	L01XC18	DB09037

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Platinum-Resistant Primary Peritoneal Carcinoma	European Union	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Iceland	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Liechtenstein	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Norway	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	European Union	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Iceland	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Liechtenstein	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Norway	Merck & Co., Inc.	02 Apr 2026
Mismatch repair-deficient Colonic Cancer	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Mismatch repair-deficient Colonic Cancer	United States	Merck Sharp & Dohme LLC	10 Feb 2026
Neoplasms	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Neoplasms	United States	Merck Sharp & Dohme LLC	10 Feb 2026
Ovarian Cancer	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Ovarian Cancer	United States	Merck Sharp & Dohme LLC	10 Feb 2026
Muscle Invasive Bladder Carcinoma	United States	Merck Sharp & Dohme Corp.	21 Nov 2025
Muscle Invasive Bladder Carcinoma	United States	Merck Sharp & Dohme LLC	21 Nov 2025
Locally Advanced Head and Neck Squamous Cell Carcinoma	European Union	Merck Sharp & Dohme BV	30 Oct 2025
Locally Advanced Head and Neck Squamous Cell Carcinoma	Iceland	Merck Sharp & Dohme BV	30 Oct 2025
Locally Advanced Head and Neck Squamous Cell Carcinoma	Liechtenstein	Merck Sharp & Dohme BV	30 Oct 2025
Locally Advanced Head and Neck Squamous Cell Carcinoma	Norway	Merck Sharp & Dohme BV	30 Oct 2025

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Platinum-Resistant Ovarian Carcinoma	NDA/BLA	United States	Merck & Co., Inc.	20 Oct 2025
Small intestine carcinoma	NDA/BLA	European Union	Merck Sharp & Dohme Corp.	25 Mar 2022
Non-small cell lung cancer stage I	Phase 3	United States	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Australia	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Canada	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Taiwan Province	Merck Sharp & Dohme LLC	04 May 2026
MSS/pMMR/MSI-L Endometrial Carcinoma	Phase 3	China	MSD R&D (China) Co. Ltd.	31 Aug 2025
Platinum-Resistant Ovarian Carcinoma	Phase 3	United States	Mural Oncology, Inc.	10 Jan 2022
Platinum-Resistant Ovarian Carcinoma	Phase 3	Australia	Mural Oncology, Inc.	10 Jan 2022
Platinum-Resistant Ovarian Carcinoma	Phase 3	Austria	Mural Oncology, Inc.	10 Jan 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02617849 (Pubmed \| Oncoimmunology)	Phase 2	Melanoma	30	Pembrolizumab and Carboplatin/ Paclitaxel	zzpzwihjdi(rzadysqciz) = tqzshlxajn mhwayljwhy (wwswgbnvaf ) View more	Negative	31 Dec 2026
NCT03213041 (CTgov)	Phase 2	Breast cancer recurrent \| Triple Negative Breast Cancer \| Metastatic breast cancer ... View more	12	Laboratory Biomarker Analysis+Carboplatin+Pembrolizumab	fklvchjkwc(djocmhjsnz) = mplfnjilow hqaiionlxw (iqzpiuhiei, kglheoggnm - wcenlpbmrp) View more	-	17 Jun 2026
NCT03657641 (CTgov)	Phase 1/2	Metastatic Colorectal Carcinoma	73	regorafenib+Pembrolizumab (Phase I, Dose Level 1)	nljoalrngy = zzfknaqqfk ebmsnogoxl (oltyykgzei, qknmtagjxb - hgwyupuihc) View more	-	16 Jun 2026
				regorafenib+Pembrolizumab (Phase I, Dose Level 2)	nljoalrngy = xocybgvknn ebmsnogoxl (oltyykgzei, qnsdbohiju - oempscnifj) View more
NCT04632459 (CTgov)	Phase 2	Metastatic gastric adenocarcinoma \| Metastatic Gastric Carcinoma	26	pembrolizumab+ramucirumab	pwfbqbmwgu = kbvlquahox ytaikaxcqu (ifkwjrdemq, mblzxwztwc - touztejioi) View more	-	05 Jun 2026
NCT04895735 (MC200708, CTgov)	Phase 2	Salivary gland cancer recurrent \| Metastatic salivary gland cancer \| Adenoid Cystic Carcinoma	45	pembrolizumab+pemetrexed disodium (Cohort A (Adenoid Cystic Carcinoma))	crkckebvsb = mcnvzvgdsl npwiupkbyi (vlmdwoxcco, chrhpkuhhj - fxqxwzwqsx) View more	-	04 Jun 2026
				pembrolizumab+pemetrexed disodium (Cohort A1 (ACC Patients Enrolled Starting With MCCC Amendment 3))	crkckebvsb = kbfkirvkie npwiupkbyi (vlmdwoxcco, pmesqrwwhl - frqwnlpeck)
NCT04955743 (CTgov)	Phase 2	Renal Cell Carcinoma \| Metastatic melanoma \| Brain metastases	18	Pembrolizumab+Lenvatinib (Cohort 1: Melanoma)	dtojnujtgy = gtyzaerlfb ursokdrzdc (qozltykyjh, ueffbsqdkg - tmivktplrj) View more	-	04 Jun 2026
				Pembrolizumab+Lenvatinib (Cohort 2: Renal Cell Carcinoma)	dtojnujtgy = mzecndeobz ursokdrzdc (qozltykyjh, hmotihcabh - kqccvvfsoj) View more
NCT03797326 (LEAP-005, Pubmed \| Clin Colorectal Cancer)	Phase 2	Colorectal Cancer	135	Lenvatinib Plus Pembrolizumab	zxrtpgxzsx(qhoyjylzui) = smzatwxgrp yoaysycfbr (ngffjflpcw, 8 - 23) View more	Positive	01 Jun 2026
				Lenvatinib	zxrtpgxzsx(qhoyjylzui) = rznudicuot yoaysycfbr (ngffjflpcw, 1 - 22) View more
NCT03040999 (KEYNOTE-412, ASCO2026)	Phase 3	Locally Advanced Head and Neck Squamous Cell Carcinoma PD-L1 CPS ≥10	382	Pembrolizumab plus chemoradiotherapy	rbusqkoelo(pxsxxewlpr) = fyspicsbvv aaiquecuss (pfmaxlxjsc ) View more	Positive	29 May 2026
				placebo plus chemoradiotherapy	rbusqkoelo(pxsxxewlpr) = fttpsknaud aaiquecuss (pfmaxlxjsc ) View more
NCT04454528 (ASCO2026)	Phase 1/2	Early Stage Breast Carcinoma	30	Radiotherapy + Pembrolizumab	daeqjxcyhl(uztfgahxcr) = dcpznymxdt eugblwjmqn (bclnzrrauf ) View more	Positive	29 May 2026
				Pembrolizumab + Radiotherapy	daeqjxcyhl(uztfgahxcr) = deuvdnahlk eugblwjmqn (bclnzrrauf ) View more
NCT03603223 (ASCO2026)	Phase 2	Leukoplakia	16	Pembrolizumab 200 mg	chvsopwpee(rxyxuibyta) = jnfkfujckm kxqovqngfa (zwrluhijwf ) View more	Positive	29 May 2026

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Pembrolizumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation